Atara Biotherapeutics, a company that develops treatments for patients with cancer, autoimmune and viral diseases, announced Oct. 25 that its general counsel plans on leaving her role, but will remain with the company as a consultant until early April.

Mina Kim, senior vice president, corporate strategy and general counsel, was not available for comment Monday. In a news release announcing her departure, the company said a replacement has not yet been named, and the company,based in South San Francisco, will begin the process of looking for a new general counsel.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]